title: Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.
abstract: OBJECTIVE
  Nodal peripheral T-cell lymphomas (PTCLs) have particularly poor prognoses. Few data enabling establishment of an accepted standard treatment modality for PTCLs are available. We hypothesized that fludarabine-based regimens are tolerable and effective in treatment for nodal PTCLs. Therefore, this study was to analyze the toxicity of, response rate for, and outcome of treatment for nodal PTCLs with oral fludarabine, doxorubicin, and dexamethasone (FAD).
  
  
  METHODS
  Patients with PTCLs received FAD every 28 days, consisting of oral fludarabine at 40 mg/m(2) on days 1-3, doxorubicin at 50 mg/m(2) on day 1, and oral dexamethasone at 20 mg/day on days 1-5. Patients who did not exhibit disease progression received at least four courses of treatment.
  
  
  RESULTS
  Thirty-one of 35 patients with previously untreated nodal PTCLs enrolled in the study from 2007 to 2008 were evaluable. The incidence of grade 3-4 neutropenia was 55%. Nine patients had to have dose reductions of fludarabine and doxorubicin, none of whom had grade 3 or 4 toxic effects at the lower dose. Five of 31 patients had pneumonitis. No treatment-related mortality occurred. The response rate for the entire patient population was 71%, and the complete remission rate was 48%. The PFS and OS rates at 2 years were 54.2 and 77.1%, respectively. Four patients had died of cancer progression at the time of this analysis. The serum lactate dehydrogenase level had a significant effect on PFS and OS.
  
  
  CONCLUSIONS
  The FAD regimen had encouraging efficacy with an acceptable toxicity profile in patients with nodal PTCLs.
authors.affiliation: Department of Medical Oncology, Fudan University Shanghai Cancer center, 270 Dong-An Road, Shanghai 200032, People's Republic of China.
authors.forename: Xiao-Jian
authors.initials: XJ
authors.lastname: Liu
authors.forename: Ye
authors.initials: Y
authors.lastname: Guo
authors.forename: Yun
authors.initials: Y
authors.lastname: Fan
authors.forename: Kang-Sheng
authors.initials: KS
authors.lastname: Gu
authors.forename: Jun-Ning
authors.initials: JN
authors.lastname: Cao
authors.forename: Xiang-Hua
authors.initials: XH
authors.lastname: Wu
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
authors.forename: Xiao-Qiu
authors.initials: XQ
authors.lastname: Li
authors.forename: Chao-Fu
authors.initials: CF
authors.lastname: Wang
authors.forename: Xiao-Nan
authors.initials: XN
authors.lastname: Hong
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008198:Lymph Nodes / Q000473:pathology; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D011446:Prospective Studies; D015996:Survival Rate; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D014839:Vomiting / Q000139:chemically induced
chemical_list: D003907:Dexamethasone; D004317:Doxorubicin; D014740:Vidarabine; C024352:fludarabine